Literature DB >> 34955419

External radiotherapy for prostatic cancers.

R de Crevoisier1, S Supiot2, G Créhange3, P Pommier4, I Latorzeff5, O Chapet6, D Pasquier7, P Blanchard8, U Schick9, V Marchesi10, P Sargos11, C Hennequin12.   

Abstract

We present the update of the recommendations of the French society of oncological radiotherapy on external radiotherapy of prostate cancer. External radiotherapy is intended for all localized prostate cancers, and more recently for oligometastatic prostate cancers. The irradiation techniques are detailed. Intensity-modulated radiotherapy combined with prostate image-guided radiotherapy is the recommended technique. A total dose of 74 to 80Gy is recommended in case of standard fractionation (2Gy per fraction). Moderate hypofractionation (total dose of 60Gy at a rate of 3Gy per fraction over 4 weeks) in the prostate has become a standard of therapy. Simultaneous integrated boost techniques can be used to treat lymph node areas. Extreme hypofractionation (35 to 40Gy in five fractions) using stereotactic body radiotherapy can be considered a therapeutic option to treat exclusively the prostate. The postoperative irradiation technique, indicated mainly in case of biological recurrence and lymph node involvement, is detailed.
Copyright © 2021. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Cancer de la prostate; French society for radiation oncology; Guidelines; Prostate cancer; Radiation therapy; Radiothérapie; Recommandations; Société française de radiothérapie oncologique

Mesh:

Year:  2021        PMID: 34955419     DOI: 10.1016/j.canrad.2021.11.017

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  1 in total

1.  High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort.

Authors:  Delphine Marotte; Jocelyn Gal; Renaud Schiappa; Mathieu Gautier; Rabia Boulahssass; Marie-Eve Chand-Fouche; Jean-Michel Hannoun-Levi
Journal:  Clin Transl Radiat Oncol       Date:  2022-05-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.